Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLevy, Benjamin
dc.contributor.authorCappuzzo, Federico
dc.contributor.authorYoneshima, Yasuto
dc.contributor.authorReck, Martin
dc.contributor.authorYang, James Chih-Hsin
dc.contributor.authorFELIP, ENRIQUETA
dc.date.accessioned2023-09-07T12:07:06Z
dc.date.available2023-09-07T12:07:06Z
dc.date.issued2023-07
dc.identifier.citationLevy BP, Felip E, Reck M, Yang JC, Cappuzzo F, Yoneshima Y, et al. TROPION-Lung08: Phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC. Futur Oncol. 2023 Jul;19(21):1461–72.
dc.identifier.issn1744-8301
dc.identifier.urihttps://hdl.handle.net/11351/10253
dc.descriptionAntibody–drug conjugate; Immuno-oncology; Non-small-cell lung cancer
dc.description.abstractPembrolizumab monotherapy is a standard first-line treatment for PD-L1–high advanced non-small-cell lung cancer (NSCLC) without actionable genomic alterations (AGA). However, few patients experience long-term disease control, highlighting the need for more effective therapies. Datopotamab deruxtecan (Dato-DXd), a novel trophoblast cell-surface antigen 2-directed antibody–drug conjugate, showed encouraging safety and antitumor activity with pembrolizumab in advanced NSCLC. We describe the rationale and design of TROPION-Lung08, a phase III study evaluating safety and efficacy of first-line Dato-DXd plus pembrolizumab versus pembrolizumab monotherapy in patients with advanced/metastatic NSCLC without AGAs and with PD-L1 tumor proportion score ≥50%. Primary end points are progression-free survival and overall survival; secondary end points include objective response rate, duration of response, safety and presence of antidrug antibodies.
dc.language.isoeng
dc.publisherFuture Medicine
dc.relation.ispartofseriesFuture Oncology;19(21)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectPulmons - Càncer - Tractament
dc.subjectQuimioteràpia combinada
dc.subjectMedicaments antineoplàstics - Ús terapèutic
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.mesh/drug therapy
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols
dc.titleTROPION-Lung08: phase III study of datopotamab deruxtecan plus pembrolizumab as first-line therapy for advanced NSCLC
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.2217/fon-2023-0230
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decs/farmacoterapia
dc.subject.decsprotocolos de quimioterapia antineoplásica combinada
dc.relation.publishversionhttps://doi.org/10.2217/fon-2023-0230
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Levy BP] The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Medicine, Washington, USA. [Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Reck M] Lung Clinic Grosshansdorf, Airway Research Center North (ARCN), Grosshansdorf, Germany. [Yang JC] Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. [Cappuzzo F] Istituto Nazionale Tumori Regina Elena, Rome, Italy. [Yoneshima Y] Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
dc.identifier.pmid37249038
dc.identifier.wos000998579700001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record